MA33212B1 - Procedes d'amelioration de pharmacocinetique - Google Patents

Procedes d'amelioration de pharmacocinetique

Info

Publication number
MA33212B1
MA33212B1 MA34273A MA34273A MA33212B1 MA 33212 B1 MA33212 B1 MA 33212B1 MA 34273 A MA34273 A MA 34273A MA 34273 A MA34273 A MA 34273A MA 33212 B1 MA33212 B1 MA 33212B1
Authority
MA
Morocco
Prior art keywords
methods
improving pharmacokinetics
pharmacokinetics
improving
cytochrome
Prior art date
Application number
MA34273A
Other languages
Arabic (ar)
English (en)
Inventor
Jonathan Q Tran
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33212B1 publication Critical patent/MA33212B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'objectif de la présente invention est d'élever le taux sanguin d'un composé de formule I par co-administration avec un inhibiteur du cytochrome P450.
MA34273A 2009-04-25 2010-04-22 Procedes d'amelioration de pharmacocinetique MA33212B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17272209P 2009-04-25 2009-04-25
PCT/EP2010/055317 WO2010122087A1 (fr) 2009-04-25 2010-04-22 Procédés d'amélioration de pharmacocinétique

Publications (1)

Publication Number Publication Date
MA33212B1 true MA33212B1 (fr) 2012-04-02

Family

ID=42236685

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34273A MA33212B1 (fr) 2009-04-25 2010-04-22 Procedes d'amelioration de pharmacocinetique

Country Status (36)

Country Link
US (4) US20100272682A1 (fr)
EP (1) EP2421527B1 (fr)
JP (1) JP5523552B2 (fr)
KR (1) KR101471238B1 (fr)
CN (2) CN102413827A (fr)
AR (1) AR076388A1 (fr)
AU (1) AU2010240893B2 (fr)
BR (1) BRPI1015147B1 (fr)
CA (1) CA2758644C (fr)
CL (1) CL2011002643A1 (fr)
CO (1) CO6440593A2 (fr)
CR (1) CR20110551A (fr)
DK (1) DK2421527T3 (fr)
EC (1) ECSP11011420A (fr)
ES (1) ES2683736T3 (fr)
HK (1) HK1215858A1 (fr)
HR (1) HRP20181306T1 (fr)
HU (1) HUE040182T2 (fr)
IL (1) IL215620A (fr)
LT (1) LT2421527T (fr)
MA (1) MA33212B1 (fr)
MX (2) MX2011011105A (fr)
MY (1) MY169734A (fr)
NZ (1) NZ595917A (fr)
PE (1) PE20120638A1 (fr)
PL (1) PL2421527T3 (fr)
PT (1) PT2421527T (fr)
RS (1) RS57501B1 (fr)
RU (1) RU2591830C2 (fr)
SG (1) SG175328A1 (fr)
SI (1) SI2421527T1 (fr)
TR (1) TR201809600T4 (fr)
TW (1) TWI468160B (fr)
UA (1) UA103801C2 (fr)
WO (1) WO2010122087A1 (fr)
ZA (1) ZA201107421B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045266A1 (fr) * 2008-10-15 2010-04-22 Intermune, Inc. Peptides antiviraux therapeutiques
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2455068A1 (fr) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Composition pharmaceutique pour le traitement d'infections par VHC
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
EP2802595B1 (fr) 2012-01-11 2016-01-06 AbbVie Inc. Procédés de préparation d'inhibiteurs de protéase du vhc
MX2014015942A (es) * 2012-06-27 2015-07-17 Abbvie Inc Tratamiento de combinacion con abt-450 y ritonavir y e. g. abt-072 y/o abt-333 para utilizarse en el tratamiento del vhc.
BR112015007887A2 (pt) 2012-10-08 2017-07-04 Abbvie Inc compostos úteis para produzir inibidores hcv protease
PL3137078T3 (pl) * 2014-05-01 2019-08-30 Eiger Biopharmaceuticals, Inc. Leczenie zakażenia wirusem zapalenia wątroby typu delta
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334250D1 (de) 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
IL141438A0 (en) 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
SK742003A3 (en) * 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20050085681A (ko) 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
CN1893978A (zh) * 2003-10-27 2007-01-10 沃泰克斯药物股份有限公司 用于hcv治疗的组合
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment

Also Published As

Publication number Publication date
CR20110551A (es) 2011-12-13
BRPI1015147B1 (pt) 2022-03-08
US20180318267A1 (en) 2018-11-08
AU2010240893A1 (en) 2011-11-03
RU2011142651A (ru) 2013-05-27
HUE040182T2 (hu) 2019-02-28
KR101471238B1 (ko) 2014-12-12
MX351185B (es) 2017-10-04
WO2010122087A1 (fr) 2010-10-28
NZ595917A (en) 2014-02-28
UA103801C2 (ru) 2013-11-25
JP2012524753A (ja) 2012-10-18
CA2758644A1 (fr) 2010-10-28
CL2011002643A1 (es) 2012-05-25
AR076388A1 (es) 2011-06-08
PL2421527T3 (pl) 2018-10-31
DK2421527T3 (en) 2018-08-13
SI2421527T1 (sl) 2018-09-28
US20170119739A1 (en) 2017-05-04
US20200230112A1 (en) 2020-07-23
PE20120638A1 (es) 2012-05-26
IL215620A0 (en) 2012-01-31
KR20120014170A (ko) 2012-02-16
TR201809600T4 (tr) 2018-07-23
HK1215858A1 (zh) 2016-09-23
HRP20181306T1 (hr) 2018-10-19
SG175328A1 (en) 2011-11-28
US10918626B2 (en) 2021-02-16
PT2421527T (pt) 2018-08-02
BRPI1015147A2 (pt) 2018-01-30
MY169734A (en) 2019-05-14
CN105233249A (zh) 2016-01-13
EP2421527A1 (fr) 2012-02-29
EP2421527B1 (fr) 2018-06-13
CO6440593A2 (es) 2012-05-15
RS57501B1 (sr) 2018-10-31
LT2421527T (lt) 2018-09-10
ECSP11011420A (es) 2011-11-30
CN102413827A (zh) 2012-04-11
US20100272682A1 (en) 2010-10-28
TWI468160B (zh) 2015-01-11
RU2591830C2 (ru) 2016-07-20
MX2011011105A (es) 2011-11-18
TW201041582A (en) 2010-12-01
JP5523552B2 (ja) 2014-06-18
ZA201107421B (en) 2022-11-30
CA2758644C (fr) 2018-01-09
ES2683736T3 (es) 2018-09-27
IL215620A (en) 2015-10-29
AU2010240893B2 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
MY169734A (en) Methods for improving pharmacokinetics
TN2011000400A1 (en) Inhibitors of beta-secretase
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
MA32231B1 (fr) Composés organiques
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
TN2011000654A1 (fr) Sulfonamides heterocycliques leurs utilisations et compositions pharmaceutiques les contenant
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
ES2531056T3 (es) Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1
CO6351737A2 (es) Amidofenoxiindazoles utiles como inhibidores de c-met
MX342377B (es) Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
UA108738C2 (uk) Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
MY172860A (en) Dimethyl-benzoic acid compounds
MX2012001617A (es) Derivados de 5-fluoro-2-oxopirimidina-1 (2h)-carboxamida substituida-n1.
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
NZ712660A (en) Dicarboxylic acid compound
SG11201808171PA (en) Griseofulvin compound
RU2012146325A (ru) Терапевтическое средство или профилактическое средство для лечения фибромиалгии